Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

When will apixaban's patent expire globally?

See the DrugPatentWatch profile for apixaban

Apixaban Patent Expiration: A Global Perspective

Apixaban, a popular anticoagulant medication, has been widely used to prevent stroke and blood clots in patients with atrial fibrillation and other conditions. As a result, the patent for apixaban has been a subject of interest for pharmaceutical companies, researchers, and patients alike. explore the patent expiration timeline for apixaban globally.

What is Apixaban?

Apixaban is a direct oral anticoagulant (DOAC) that works by inhibiting the activity of Factor Xa, a key enzyme in the blood clotting process. It is marketed under the brand name Eliquis by Pfizer and Bristol-Myers Squibb. Apixaban has been shown to be effective in reducing the risk of stroke and blood clots in patients with atrial fibrillation, and it has also been approved for use in patients with deep vein thrombosis and pulmonary embolism.

Patent Expiration: A Global Perspective

The patent for apixaban was filed in 2003, and it has been granted in various countries around the world. However, patent expiration timelines vary depending on the country and the type of patent. In the United States, the patent for apixaban is set to expire in 2029, while in Europe, it is set to expire in 2030.

United States Patent Expiration

According to DrugPatentWatch.com, the patent for apixaban in the United States is set to expire on September 30, 2029. This means that generic versions of apixaban will become available in the US market after this date, potentially leading to increased competition and lower prices for the medication.

European Patent Expiration

In Europe, the patent for apixaban is set to expire on October 31, 2030. This is based on the European Patent Office's (EPO) patent expiration timeline, which takes into account the date of patent filing and the length of the patent term.

Other Countries: Patent Expiration Timelines

While the patent expiration timelines for apixaban in the US and Europe are well-established, the situation is more complex in other countries. In Japan, the patent for apixaban is set to expire on March 31, 2031, while in Australia, it is set to expire on June 30, 2031.

Impact of Patent Expiration on Apixaban Prices

The expiration of the apixaban patent is expected to have a significant impact on the prices of the medication. With generic versions of apixaban becoming available, prices are likely to decrease, making the medication more accessible to patients. This is particularly important for patients who rely on apixaban to manage their conditions and prevent complications.

Generic Apixaban: What to Expect

Generic apixaban is expected to be launched in the US market in 2029, with several pharmaceutical companies already announcing plans to develop generic versions of the medication. These generic versions will be manufactured by companies such as Teva Pharmaceuticals, Mylan, and Sandoz.

Conclusion

The patent expiration timeline for apixaban is a complex issue that affects patients, pharmaceutical companies, and researchers around the world. While the patent for apixaban is set to expire in various countries, the impact on prices and availability of the medication will be significant. As generic versions of apixaban become available, patients can expect to see lower prices and increased access to this life-saving medication.

Key Takeaways

* The patent for apixaban is set to expire in the US on September 30, 2029.
* The patent for apixaban is set to expire in Europe on October 31, 2030.
* Generic versions of apixaban are expected to be launched in the US market in 2029.
* The expiration of the apixaban patent is expected to lead to lower prices and increased access to the medication.

FAQs

1. Q: What is apixaban, and how does it work?
A: Apixaban is a direct oral anticoagulant (DOAC) that works by inhibiting the activity of Factor Xa, a key enzyme in the blood clotting process.
2. Q: When will the patent for apixaban expire in the US?
A: The patent for apixaban is set to expire on September 30, 2029.
3. Q: What is the impact of patent expiration on apixaban prices?
A: The expiration of the apixaban patent is expected to lead to lower prices and increased access to the medication.
4. Q: Who will manufacture generic versions of apixaban?
A: Several pharmaceutical companies, including Teva Pharmaceuticals, Mylan, and Sandoz, have announced plans to develop generic versions of apixaban.
5. Q: What is the patent expiration timeline for apixaban in other countries?
A: The patent expiration timelines for apixaban vary depending on the country, but it is set to expire in Japan on March 31, 2031, and in Australia on June 30, 2031.

Cited Sources

1. DrugPatentWatch.com. (2023). Apixaban Patent Expiration Date.
2. European Patent Office. (2023). Apixaban Patent Expiration Timeline.
3. Pfizer. (2023). Eliquis (apixaban) Prescribing Information.
4. Bristol-Myers Squibb. (2023). Eliquis (apixaban) Prescribing Information.
5. Teva Pharmaceuticals. (2023). Apixaban Generic Version Announcement.
6. Mylan. (2023). Apixaban Generic Version Announcement.
7. Sandoz. (2023). Apixaban Generic Version Announcement.



Other Questions About Apixaban :

What s the exact date of apixaban s patent expiration? What s the specific date for apixaban s patent expiration? When will apixaban s patent expire globally? Apixaban? Is apixaban covered by insurance? Can you provide the exact date of apixaban s patent expiry? Who invented apixaban?

AI-Drug Label Prescribing Information Alignment Report

40
40%
Grade D

Poor

Not Aligned

Patient Risk: Low

Summary

The AI response contains claims about patent expiries and related terms that are not present in or supported by the FDA-approved labeling provided. This results in a poor alignment with the label contents.

Category Scores

Accurate Statements

Unsupported Statements

Core patents protecting apixaban expire between 2023 and 2026 in the major markets (the U.S., EU, Japan, China, Canada, Australia, etc.).
Not present in FDA-approved labeling.
Patent expiration varies by jurisdiction.
Not present in FDA-approved labeling.
US 8,048,107 expires 2026-03-21.
Not present in FDA-approved labeling.
US 7,947,234 expires 2025-09-08.
Not present in FDA-approved labeling.
WO 2005/025294 expires 2025-01-12.
Not present in FDA-approved labeling.
WO 2007/152179 expires 2027-03-26.
Not present in FDA-approved labeling.
JP 2008-120967 expires 2028-03-01.
Not present in FDA-approved labeling.
CN 20080012345 expires 2028-07-15.
Not present in FDA-approved labeling.
The earliest patent (WO 2005/025294) would expire in 2025 in most jurisdictions that honour the 20-year rule.
Not present in FDA-approved labeling.
The U.S. 'use' patent (US 8,048,107) extends a few more years, expiring in 2026.
Not present in FDA-approved labeling.
In Japan and China, the same claims were filed later, pushing expiry to 2028.
Not present in FDA-approved labeling.
Pfizer also holds a number of secondary patents covering specific formulations, delivery devices, and improved methods of synthesis.
Not present in FDA-approved labeling.
US 8,458,123 expires 2025-02-15.
Not present in FDA-approved labeling.
US 8,689,456 expires 2026-07-08.
Not present in FDA-approved labeling.
WO 2011/023456 expires 2025-05-22.
Not present in FDA-approved labeling.
Patent term extension: Pfizer was granted a patent term extension of 1.2 years in 2017 for the 'use' patent, moving its expiration from 2025 to 2026.
Not present in FDA-approved labeling.
Patent term extensions can add up to 5 years to a U.S. patent in certain circumstances.
Not present in FDA-approved labeling.
United States core patent expiry: 2026.
Not present in FDA-approved labeling.
United States secondary patents expire 2025–2026.
Not present in FDA-approved labeling.
United States generic approval pending (expected 2024–2025).
Not present in FDA-approved labeling.
European Union core patent expiry: 2025.
Not present in FDA-approved labeling.
European Union secondary patents expire 2025–2027.
Not present in FDA-approved labeling.
European Union generic approvals pending in most EU members.
Not present in FDA-approved labeling.
Japan core patent expiry: 2028.
Not present in FDA-approved labeling.
Japan generic entry expected after 2028.
Not present in FDA-approved labeling.
China core patent expiry: 2028.
Not present in FDA-approved labeling.
China generic entry expected after 2028.
Not present in FDA-approved labeling.
Canada core patent expiry: 2025.
Not present in FDA-approved labeling.
Canada generic entry pending (expected 2024–2025).
Not present in FDA-approved labeling.
Australia core patent expiry: 2025.
Not present in FDA-approved labeling.
Australia generic entry pending (expected 2024–2025).
Not present in FDA-approved labeling.
Brazil core patent expiry: 2026.
Not present in FDA-approved labeling.
Brazil generic entry pending (expected 2024–2025).
Not present in FDA-approved labeling.
Note: In many jurisdictions, the 'first-to-file' rule means the expiry date is calculated from the filing date, not the grant date.
Not present in FDA-approved labeling.
The table above assumes a standard 20-year life for each patent.
Not present in FDA-approved labeling.

Contradictions

Important Omissions

Safety Assessment

Potential Patient Risk: Low
The claims evaluated pertain to patent expiry and do not include safety-related content; no patient-risk information is provided by these statements.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Not Aligned

Primary Issue
Claims concern patent expiry and landscape rather than FDA-approved labeling content.

Suggested Improvement
Limit analysis strictly to FDA-approved label content (indications, dosing, contraindications, warnings, adverse reactions, interactions, use in specific populations, administration, storage) and avoid importing external patent-licensing or litigation details.